Amgen reports Aranesp data

AMGN said that in an open-label trial in chronic renal failure patients receiving dialysis, 28 of 42 patients (88%) receiving Aranesp darbepoeitin alfa once every 3 weeks maintained the study target hemoglobin range. These 28 patients were switched to once monthly doses, and of the 22 patients completing the 20-week evaluation, 19 patients (86%) maintained the study target hemoglobin range. Aranesp is approved in the U.S., Europe and elsewhere to treat anemia associated with chronic renal failure as a once weekly dose, or, in certain patients, once every two weeks. ...